BioCardia, Inc. (BCDA) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
BCDA Revenue Growth
Revenue Breakdown (FY 2023)
BCDA's revenue distribution by segment and geography for fiscal year 2023
By Product/Segment
BCDA Revenue Analysis (2013–2024)
As of May 8, 2026, BioCardia, Inc. (BCDA) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q3 2025) recorded $0 in revenue.
Looking at the longer-term picture, BCDA's 5-year compound annual growth rate (CAGR) stands at -39.4%, indicating revenue contraction over this period. The company achieved its highest annual revenue of $1.4 million in 2022.
Revenue diversification analysis shows BCDA's business is primarily driven by Collaboration Agreement (100%). With over half of revenue concentrated in Collaboration Agreement, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including MCRB, ANIK (+23.2% YoY), and NVCR (+8.5% YoY). Compare BCDA vs MCRB →
BCDA Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| BCDACurrent | $0 | - | -39.4% | -13794.8% | |
 MCRB | $789,000 | - | -52.7% | -11910.1% | |
 ANIK | $113M | +23.2% | -2.9% | -9.8% | |
 NVCR | $655M | +8.5% | +5.8% | -23.5% | |
 ADMA | $510M | +11.0% | +64.6% | 37.5% | |
 VCEL | $276M | +22.4% | +17.3% | 4.0% |
BCDA Historical Revenue Data (2013–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $58K | -87.8% | $-4,329,000 | -7463.8% | $-8,000,999 | -13794.8% |
| 2023 | $477K | -64.7% | $-7,249,000 | -1519.7% | $-11,644,000 | -2441.1% |
| 2022 | $1.4M | +33.2% | $-7,482,000 | -553.4% | $-11,901,000 | -880.3% |
| 2021 | $1.0M | +600.0% | $375K | 36.9% | $-12,630,000 | -1244.3% |
| 2020 | $145K | -79.6% | $141K | 97.2% | $-15,529,000 | -10709.7% |
| 2019 | $710K | +13.6% | $352K | 49.6% | $-14,213,000 | -2001.8% |
| 2018 | $625K | +30.5% | $108K | 17.3% | $-14,102,000 | -2256.3% |
| 2017 | $479K | -16.8% | $-211,000 | -44.1% | $-12,405,000 | -2589.8% |
| 2016 | $576K | +11.4% | $-170,000 | -29.5% | $-7,608,000 | -1320.8% |
| 2015 | $517K | +21.1% | $-1,675,000 | -324.0% | $319K | 61.7% |
See BCDA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BCDA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BCDA vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonBCDA — Frequently Asked Questions
Quick answers to the most common questions about buying BCDA stock.
Is BCDA's revenue growth accelerating or slowing?
BCDA TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: -39.4%.
What is BCDA's long-term revenue growth rate?
BioCardia, Inc.'s 5-year revenue CAGR of -39.4% reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is BCDA's revenue distributed by segment?
BCDA reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.